Patricia Danzon

Summary

Affiliation: University of Pennsylvania
Country: USA

Publications

  1. ncbi request reprint The economics of parallel trade
    P M Danzon
    Health Care Department, Wharton School, University of Pennsylvania, Philadelphia, USA
    Pharmacoeconomics 13:293-304. 1998
  2. doi request reprint Drug pricing and value in oncology
    Patricia M Danzon
    University of Pennsylvania, Philadelphia, 19104, USA
    Oncologist 15:24-31. 2010
  3. doi request reprint International prices and availability of pharmaceuticals in 2005
    Patricia M Danzon
    Health Care Department, Wharton School, University of Pennsylvania, Philadelphia, USA
    Health Aff (Millwood) 27:221-33. 2008
  4. ncbi request reprint Prices and availability of biopharmaceuticals: an international comparison
    Patricia M Danzon
    Health Care Department, Wharton School at the University of Pennsylvania in Philadelphia, USA
    Health Aff (Millwood) 25:1353-62. 2006
  5. ncbi request reprint Vaccine supply: a cross-national perspective
    Patricia M Danzon
    Wharton School, University of Pennsylvania, Philadelphia, PA, USA
    Health Aff (Millwood) 24:706-17. 2005
  6. ncbi request reprint Why sole-supplier vaccine markets may be here to stay
    Patricia Danzon
    Wharton School, University of Pennsylvania, Philadelphia, PA, USA
    Health Aff (Millwood) 24:694-6. 2005
  7. ncbi request reprint Alternative strategies for Medicare payment of outpatient prescription drugs--Part B and beyond
    Patricia M Danzon
    Department of Health Care Systems, The Wharton School, University of Pennsylvania, Philadelphia, PA 19104 6218, USA
    Am J Manag Care 11:173-80. 2005
  8. ncbi request reprint Productivity in pharmaceutical-biotechnology R&D: the role of experience and alliances
    Patricia M Danzon
    University of Pennsylvania, Health Care Management Department, The Wharton School, 3641 Locust Walk, Philadelphia, PA 19104, USA
    J Health Econ 24:317-39. 2005
  9. doi request reprint Setting cost-effectiveness thresholds as a means to achieve appropriate drug prices in rich and poor countries
    Patricia M Danzon
    Health Care Management, Wharton School of University of Pennsylvania, Philadelphia, PA, USA
    Health Aff (Millwood) 30:1529-38. 2011
  10. ncbi request reprint Prices and availability of pharmaceuticals: evidence from nine countries
    Patricia M Danzon
    Wharton School s Health Care Department, University of Pennsylvania, Philadelphia, USA
    Health Aff (Millwood) . 2003

Research Grants

  1. Advanced Training in Health Service Research
    Patricia Danzon; Fiscal Year: 2007

Detail Information

Publications20

  1. ncbi request reprint The economics of parallel trade
    P M Danzon
    Health Care Department, Wharton School, University of Pennsylvania, Philadelphia, USA
    Pharmacoeconomics 13:293-304. 1998
    ..This would preserve differentials in transactions prices even if parallel trade forces convergence of wholesale prices...
  2. doi request reprint Drug pricing and value in oncology
    Patricia M Danzon
    University of Pennsylvania, Philadelphia, 19104, USA
    Oncologist 15:24-31. 2010
    ..S. data. Making such outcomes-adjusted prices available in the U.S. would be helpful to physicians, payers, and patients and indirectly constrain pricing to align with value...
  3. doi request reprint International prices and availability of pharmaceuticals in 2005
    Patricia M Danzon
    Health Care Department, Wharton School, University of Pennsylvania, Philadelphia, USA
    Health Aff (Millwood) 27:221-33. 2008
    ..Comprehensive price indexes show foreign prices to be 20-40 percent lower than U.S. manufacturer prices, but only 10-30 percent lower than U.S. public prices. Generics are cheaper in the United States than in other countries...
  4. ncbi request reprint Prices and availability of biopharmaceuticals: an international comparison
    Patricia M Danzon
    Health Care Department, Wharton School at the University of Pennsylvania in Philadelphia, USA
    Health Aff (Millwood) 25:1353-62. 2006
    ..Prices for identical formulations are not higher on average in the United States. The broader price indexes, which do not control formulation, are also not higher in the United States, after adjusting for income...
  5. ncbi request reprint Vaccine supply: a cross-national perspective
    Patricia M Danzon
    Wharton School, University of Pennsylvania, Philadelphia, PA, USA
    Health Aff (Millwood) 24:706-17. 2005
    ..High, country-specific, fixed costs, combined with price and volume uncertainty, plausibly deters these potential suppliers from attempting to enter the U.S. market...
  6. ncbi request reprint Why sole-supplier vaccine markets may be here to stay
    Patricia Danzon
    Wharton School, University of Pennsylvania, Philadelphia, PA, USA
    Health Aff (Millwood) 24:694-6. 2005
    ....
  7. ncbi request reprint Alternative strategies for Medicare payment of outpatient prescription drugs--Part B and beyond
    Patricia M Danzon
    Department of Health Care Systems, The Wharton School, University of Pennsylvania, Philadelphia, PA 19104 6218, USA
    Am J Manag Care 11:173-80. 2005
    ..Folding Part B and Part D into comprehensive contracting with health plans for full health services is likely to offer the most efficient approach to managing the drug benefit...
  8. ncbi request reprint Productivity in pharmaceutical-biotechnology R&D: the role of experience and alliances
    Patricia M Danzon
    University of Pennsylvania, Health Care Management Department, The Wharton School, 3641 Locust Walk, Philadelphia, PA 19104, USA
    J Health Econ 24:317-39. 2005
    ..Products developed in an alliance tend to have a higher probability of success, at least for the more complex phase 2 and phase 3 trials, and particularly if the licensee is a large firm...
  9. doi request reprint Setting cost-effectiveness thresholds as a means to achieve appropriate drug prices in rich and poor countries
    Patricia M Danzon
    Health Care Management, Wharton School of University of Pennsylvania, Philadelphia, PA, USA
    Health Aff (Millwood) 30:1529-38. 2011
    ..Adopting this approach broadly should lead to appropriate price differences across and within countries, benefiting consumers and manufacturers alike...
  10. ncbi request reprint Prices and availability of pharmaceuticals: evidence from nine countries
    Patricia M Danzon
    Wharton School s Health Care Department, University of Pennsylvania, Philadelphia, USA
    Health Aff (Millwood) . 2003
    ..K. prices in 1999 than in 1992. Our findings suggest that U.S.-foreign price differentials are roughly in line with income and smaller for drugs than for other medical services...
  11. ncbi request reprint Closing the doughnut hole: no easy answers
    Patricia M Danzon
    Wharton School, University of Pennsylvania, Philadelphia, USA
    Health Aff (Millwood) . 2004
    ..Careful cost-effectiveness analysis would be more appropriate than trying to import other countries' price controls. Income-related subsidies are a better strategy for dealing with excessive cost sharing for low-income seniors...
  12. ncbi request reprint Cross-national price differences for pharmaceuticals: how large, and why?
    P M Danzon
    Health Care Management Department, Wharton School, University of Pennsylvania, Philadelphia 19104, USA
    J Health Econ 19:159-95. 2000
    ..Strict price regulation systematically lowers prices for older molecules and globally diffused molecules. Generic competition lowers prices in less-regulated regimes, which also have more price-elastic demand...
  13. ncbi request reprint Differential pricing for pharmaceuticals: reconciling access, R&D and patents
    Patricia M Danzon
    Wharton School, University of Pennsylvania, USA
    Int J Health Care Finance Econ 3:183-205. 2003
    ..Differential pricing could go a long way to improve LDC access to drugs that have a high income market. However, other subsidy mechanisms will be needed to promote R&D for drugs that have no high income market...
  14. ncbi request reprint Reference pricing of pharmaceuticals for Medicare: evidence from Germany, The Netherlands, and New Zealand
    Patricia M Danzon
    University of Pennsylvania, USA
    Front Health Policy Res 7:1-54. 2004
    ..S. generic market, and on research and development (R&D) and the future supply of new drugs, because of the much larger U.S. share of global pharmaceutical sales...
  15. ncbi request reprint The economics of gene therapy and of pharmacogenetics
    Patricia Danzon
    Wharton School, University of Pennsylvania, Philadelphia, PA, USA
    Value Health 5:5-13. 2002
    ..This problem with small numbers is analogous to that associated with gene therapy for monogenic diseases and may require similar remedies if society values developing treatments for these diseases...
  16. ncbi request reprint A general model of the impact of absenteeism on employers and employees
    Mark V Pauly
    Health Care Systems Department, The Wharton School, 3641 Locust Walk, Philadelphia, PA 19104 6218, USA
    Health Econ 11:221-31. 2002
    ..In the long run, workers are likely to bear much of the incidence of the costs associated with absenteeism, and therefore be the likely beneficiaries of any reduction in absenteeism...
  17. ncbi request reprint At what price?
    Patricia M Danzon
    Health Care Management Department at The Wharton School, University of Pennsylvania, Philadelphia, USA
    Nature 449:176-9. 2007
  18. ncbi request reprint The impact of price regulation on the launch delay of new drugs--evidence from twenty-five major markets in the 1990s
    Patricia M Danzon
    Health Care Systems Department, The Wharton School, University of Pennsylvania, Philadelphia, 19104 6218, USA
    Health Econ 14:269-92. 2005
    ..Controlling for expected price and volume, country effects for the likely parallel export countries are significantly negative...
  19. ncbi request reprint Welfare effects of supplementary insurance: a comment
    Patricia M Danzon
    J Health Econ 21:923-6. 2002
  20. ncbi request reprint Effect of tiered prescription copayments on the use of preferred brand medications
    Thomas S Rector
    Center for Health Care Policy and Evaluation, UnitedHealth Group, Eden Prairie, Minnesota 55344, USA
    Med Care 41:398-406. 2003
    ..How much this financial incentive affects use of preferred brands has not been widely reported. The aim of this study was to estimate the effect of tiered copayments on the choice between preferred and nonpreferred brand medications...

Research Grants1

  1. Advanced Training in Health Service Research
    Patricia Danzon; Fiscal Year: 2007
    ....